Literature DB >> 8737681

Corticotropin-releasing factor up-regulates its own receptor mRNA in the paraventricular nucleus of the hypothalamus.

T Imaki1, M Naruse, S Harada, N Chikada, J Imaki, H Onodera, H Demura, W Vale.   

Abstract

We investigated the role of CRF in regulating receptor expression in the paraventricular nucleus (PVN). First, to clarify the effect of exogenously administered CRF, 1 microgram of ovine CRF was injected into rat lateral ventricle and changes in concentration of the CRF type 1 receptor (CRF1-R) and CRF mRNA in the PVN were semiquantified after in situ hybridization. Second, we determined the effect of stress, as a stimulant of endogenous CRF secretion, on mRNA accumulation. While CRF1-R mRNA expression was low to be undetectable in the PVN of controls, both intracerebroventricular administration of CRF and restraint significantly increased CRF1-R and CRF signals in the parvocellular PVN. Thus CRF may modulate CRF production and release from the PVN, by regulating CRF1-R expression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8737681     DOI: 10.1016/0169-328x(96)00011-3

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  19 in total

1.  Immunocytochemical distribution of corticotropin-releasing hormone receptor type-1 (CRF(1))-like immunoreactivity in the mouse brain: light microscopy analysis using an antibody directed against the C-terminus.

Authors:  Y Chen; K L Brunson; M B Müller; W Cariaga; T Z Baram
Journal:  J Comp Neurol       Date:  2000-05-08       Impact factor: 3.215

2.  Paraventricular nucleus corticotrophin releasing hormone contributes to sympathoexcitation via interaction with neurotransmitters in heart failure.

Authors:  Yu-Ming Kang; Ai-Qun Zhang; Xiu-Fang Zhao; Jeffrey P Cardinale; Carrie Elks; Xi-Mei Cao; Zhen-Wen Zhang; Joseph Francis
Journal:  Basic Res Cardiol       Date:  2011-02-02       Impact factor: 17.165

3.  Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems.

Authors:  K H Skelton; C B Nemeroff; D L Knight; M J Owens
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

4.  Corticotropin-releasing factor mRNA and substance P receptor binding in the paraventricular hypothalamic nucleus, central nucleus of the amygdala, and locus coeruleus of Sprague-Dawley rats following restraint-induced stress.

Authors:  Bang H Hwang; Jason Katner; Smriti Iyengar
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

5.  Repeated restraint stress lowers the threshold for response to third ventricle CRF administration.

Authors:  Ruth B S Harris
Journal:  Horm Behav       Date:  2016-12-23       Impact factor: 3.587

6.  Increased expression level of corticotropin-releasing hormone in the amygdala and in the hypothalamus in rats exposed to chronic unpredictable mild stress.

Authors:  Shan-Shan Wang; Xue-Bo Yan; Michel A Hofman; Dick F Swaab; Jiang-Ning Zhou
Journal:  Neurosci Bull       Date:  2010-08       Impact factor: 5.203

7.  Endocrine and gene expression changes following forced swim stress exposure during cocaine abstinence in mice.

Authors:  Jessica N Cleck; Laurel E Ecke; Julie A Blendy
Journal:  Psychopharmacology (Berl)       Date:  2008-08-03       Impact factor: 4.530

8.  Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogen-activated protein kinase pathway.

Authors:  Shun-Guang Wei; Yang Yu; Zhi-Hua Zhang; Robert B Felder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

Review 9.  CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome.

Authors:  Y Taché; V Martinez; L Wang; M Million
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

Review 10.  The central corticotropin releasing factor system during development and adulthood.

Authors:  Aniko Korosi; Tallie Z Baram
Journal:  Eur J Pharmacol       Date:  2008-01-19       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.